Irritable bowel syndrome: Bacteria and inflammation - Clinical relevance now

Current Treatment Options in Gastroenterology

Volumn 10, Issue 4, 2007, Pages 312-321

  Spiller, Robin C ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CROMOGLYCATE DISODIUM; DOXYCYCLINE; ISPAGULA; METRONIDAZOLE; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PREDNISOLONE; PROBIOTIC AGENT; RIFAXIMIN; SCOPOLAMINE BUTYL BROMIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANTIBIOTIC THERAPY; BACTERIAL OVERGROWTH; BIFIDOBACTERIUM LONGUM INFANTIS; BLOATING; CLINICAL TRIAL; COLON FLORA; DIARRHEA; ENTERITIS; FLATULENCE; HUMAN; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; MONOTHERAPY; PH; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 34547604857     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0074-3     Document Type: Review

References (52)

1. Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003, 98:412-419.
2. Riordan SM, McIver CJ, Walker BM, et al.: The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol 1996, 91:1795-1803.
3. Posserud I, Stotzer PO, Bjornsson ES, et al.: Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007, 56:802-808.
4. Malinen E, Rinttila T, Kajander K, et al.: Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005, 100:373-382.
5. Mendall MA, Kumar D: Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur J Gastroenterol Hepatol 1998, 10:59-62.
6. Maxwell PR, Rink E, Kumar D, Mendall MA: Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 2002, 97:104-108.
7. King TS, Elia M, Hunter JO: Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998, 352:1187-1189.
8. Brigidi P, Swennen E, Vitali B, et al.: PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption. Int J Food Microbiol 2003, 81:203-209.
9. MacFarlane S, MacFarlane GT, Cummings JH: Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther 2006, 24:701-714.
10. Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004, 126:1620-1633.
11. Ghosh S, van Heel D, Playford RJ: Probiotics in inflammatory bowel disease: is it all gut flora modulation? Gut 2004, 53:620-622.
12. Verdu EF, Bercik P, Verma-Gandhu M, et al.: Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006, 55:182-190.
13. Cummings JH, Christie S, Cole TJ: A study of fructo oligosaccharides in the prevention of travellers' diarrhoea. Aliment Pharmacol Ther 2001, 15:1139-1145.
14. Spiller RC: Postinfectious irritable bowel syndrome. Gastroenterology 2003, 124:1662-1671.
15. Dunlop SP, Jenkins D, Neal KR, Spiller RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003, 125:1651-1659.
16. Bueno L, Fioramonti J, Garcia-Villar R: Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. III. Visceral afferent pathways: a source of new therapeutic targets for abdominal pain. Am J Physiol Gastrointest Liver Physiol 2000, 278:G670-G676.
17. Bernstein CN, Niazi N, Robert M, et al.: Rectal afferent function in patients with inflammatory and functional intestinal disorders. Pain 1996, 66:151-161.
18. Verma-Gandhu M, Verdu EF, Bercik P, et al.: Visceral pain perception is determined by the duration of colitis and associated neuropeptide expression in the mouse. Gut 2007, 56:358-364.
19. Gwee KA, Leong YL, Graham C, et al.: The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999, 44:400-406.
20. Dunlop SP, Coleman NS, Blackshaw E, et al.: Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005, 3:349-357.
21. Park JH, Rhee PL, Kim G, et al.: Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2006, 18:539-546.
22. Barbara G, Stanghellini V, De Giorgio R, et al.: Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004, 126:693-702.
23. Parker TJ, Naylor SJ, Riordan AM, Hunter JO: Management of patients with food intolerance in irritable bowel syndrome: the development and use of an exclusion diet. J Hum Nutr Diet 1995, 8:159-166.
24. Spiller R, Aziz Q, Creed F, et al.: Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007, In press.
25. Pimentel M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503-3506.
26. Brigidi P, Swennen E, Rizzello F, et al.: Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 2002, 14:290-295.
27. Pimentel M, Park S, Mirocha J, et al.: The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006, 145:557-563.
28. Anand AC, Reddy PS, Saiprasad GS, Kher SK: Does non-dysenteric intestinal amoebiasis exist? Lancet 1997, 349:89-92.
29. Di Stefano M, Strocchi A, Malservisi S, et al.: Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 2000, 14:1001-1008.
30. Sharara AI, Aoun E, Abdul-Baki H, et al.: A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006, 101:326-333.
31. Vanderhoof JA, Whitney DB, Antonson DL, et al.: Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999, 135:564-568.
32. Guandalini S, Pensabene L, Zikri MA, et al.: Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr 2000, 30:54-60.
33. O'Sullivan MA, O'Morain CA: Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000, 32:294-301.
34. Bausserman M, Michail S: The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 2005, 147:197-201.
35. Kajander K, Hatakka K, Poussa T, et al.: A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005, 22:387-394.
36. Nobaek S, Johansson ML, Molin G, et al.: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000, 95:1231-1238.
37. Niedzielin K, Kordecki H, Birkenfeld B: A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001, 13:1143-1147.
38. Sen S, Mullan MM, Parker TJ, et al.: Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002, 47:2615-2620.
39. Saggioro A: Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004, 38:S104-S106.
40. Kim HJ, Camilleri M, McKinzie S, et al.: A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17:895-904.
41. Kim HJ, Vazquez Roque MI, Camilleri M, et al.: A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005, 17:687-696.
42. McCarthy J, O'Mahony L, O'Callaghan L, et al.: Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003, 52:975-980.
43. O'Mahony L, McCarthy J, Kelly P, et al.: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551.
44. Whorwell PJ, Altringer L, Morel J, et al.: Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006, 101:1581-1590.
45. Huerta C, Garcia Rodriguez LA, Wallander MA, Johansson S: Risk of irritable bowel syndrome among asthma patients. Pharmacoepidemiol Drug Saf 2002, 11:31-35.
46. Cole JA, Rothman KJ, Cabral HJ, et al.: Incidence of IBS in a cohort of people with asthma. Dig Dis Sci 2007, 52:329-335.
47. Dunlop SP, Jenkins D, Neal KR, et al.: Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003, 18:77-84.
48. Locke GR 3rd, Zinsmeister AR, Talley NJ, et al.: Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol 2000, 95:157-165.
49. Schafer E, Ewe K: The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with IBS [in German]. Fortschr Med 1990, 108:488-492.
50. Stefanini GF, Prati E, Albini MC, et al.: Oral disodium cromoglycate treatment on irritable bowel syndrome: an open study on 101 subjects with diarrheic type. Am J Gastroenterol 1992, 87:55-57.
51. Nayak AK, Karnad DR, Abraham P, Mistry FP: Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called 'chronic amebiasis.' Indian J Gastroenterol 1997, 16:137-139.
52. Niv E, Naftali T, Hallak R, Vaisman N: The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - a double blind, placebo-controlled, randomized study. Clin Nutr 2005, 24:925-931.